A cross-border Life Sciences team advised Vaccitech on the completion of its $168 million Series B, including the conversion of $43 million in convertible loan notes previously issued by Vaccitech. The financing round was led by M&G Investment Management, with further participation from new investors including Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund, and Future Planet Capital among others. The Series B was also supported by existing investors, including Oxford Sciences Innovation PLC. The proceeds from the financing will support the continued development of Vaccitech’s three infectious disease and immuno-oncology programs.
Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company’s proprietary platform comprises modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, to prime a targeted immune response with the Modified Vaccinia Ankara virus (MVA) to boost the targeted immune response against cells infected with a virus or tumor cells.
The Goodwin team was led by Andrew Harrow and Elizabeth Rhodes and included Mike Grainger, Matthew Shelley, Jack Christian, Marishka DeToy, Rob Puopolo and Duncan Greenhalgh.
For additional details on the financing round, please read the press release.